Auro Laboratories Ltd: Intrinsic Value & Share Price Analysis

Q: What is the current share price and 52-week range of Auro Laboratories Ltd?

Auro Laboratories Ltd is trading at 272.00 as of 25 April 2026, with a FY2026-2027 high of 317 and low of 159. The stock is currently in the middle of its 52-week range. Market cap stands at 169 Cr..

Q: Is Auro Laboratories Ltd financially healthy?

Key indicators: ROCE of 3.85 % is on the lower side. Dividend yield is 0.00 %.

Q: Is Auro Laboratories Ltd profitable and how is the profit trend?

Auro Laboratories Ltd reported a net profit of 2 Cr in Mar 2025 on revenue of 19 Cr. Compared to 3 Cr in Mar 2022, the net profit shows a declining trend.

Fair Value

₹141.76Overvalued by 47.88%vs CMP ₹272.00

P/E (57.4) × ROE (4.3%) × BV (₹69.90) × DY (2.00%)

₹134.72Overvalued by 50.47%vs CMP ₹272.00

MoS: -101.9% (Negative)Confidence: 53/100 (Moderate)Models: 1 Under, 5 Over

Model	Category	Value	Weight	Signal
PE-ROE	Earnings	₹142.87	33%	Over (-47.5%)
Graham Number	Earnings	₹86.34	24%	Over (-68.3%)
Net Asset Value	Assets	₹70.14	11%	Over (-74.2%)
Earnings Yield	Earnings	₹47.40	11%	Over (-82.6%)
ROCE Capital	Returns	₹385.02	13%	Under (+41.6%)
Revenue Multiple	Revenue	₹31.22	8%	Over (-88.5%)
Consensus (6 models)		₹134.72	100%	Overvalued

Key Drivers: ROE 4.3% is below cost of equity. | Wide model spread (₹31–₹385) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 0.8%

*Investments are subject to market risks

Analyst Summary

Auro Laboratories Ltd operates in the Pharmaceuticals segment, NSE: AUROLAB | BSE: 530233, current market price is ₹272.00, market cap is 169 Cr.. At a glance, stock P/E is 57.4, ROE is 4.33 %, ROCE is 3.85 %, book value is 69.9, dividend yield is 0.00 %. The latest intrinsic value estimate is ₹134.72, around 50.5% below the current price, so expectations may already be running ahead of this modelled fair value. On operating trend, latest reported sales are about ₹19 Cr versus the prior period change of -63.8%, while latest net profit is about ₹2 Cr with a prior-period change of -76.4%. The 52-week range shown on this page is 317/159, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisAuro Laboratories Ltd. is a Public Limited Listed company incorporated on 26/05/1989 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is…

This summary is generated from the stock page data available for Auro Laboratories Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

Auro Laboratories Ltd scores 54/100 (Average)

Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison

Stock Health50/100 · Moderate

ROCE 3.9% WeakROE 4.3% WeakD/E 0.07 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent

Smart Money50/100 · Moderate

Promoter holding at 52.2% Stable

Earnings Quality75/100 · Strong

OPM expanding (9% → 19%) ImprovingWorking capital: -14 days (improving) Efficient

Quarterly Momentum60/100 · Moderate

Revenue (4Q): +19% YoY GrowingProfit (4Q): -15% YoY DecliningOPM: 43.2% (up 28.5% YoY) Margin expansion

Industry Rank20/100 · Weak

P/E 57.4 vs industry 53.8 In-lineROCE 3.9% vs industry 16.4% Below peersROE 4.3% vs industry 15.2% Below peers3Y sales CAGR: -27% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 4:10 am

Market Cap	169 Cr.
Current Price	272
Intrinsic Value	₹134.72
High / Low	317/159
Stock P/E	57.4
Book Value	69.9
Dividend Yield	0.00 %
ROCE	3.85 %
ROE	4.33 %
Face Value	10.0
PEG Ratio	73.85

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Auro Laboratories Ltd

Competitors

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Auro Laboratories Ltd	169 Cr.	272	317/159	57.4	69.9	0.00 %	3.85 %	4.33 %	10.0
Lyka Labs Ltd	183 Cr.	51.2	129/44.1		28.3	0.00 %	9.91 %	9.31 %	10.0
Aarey Drugs & Pharmaceuticals Ltd	151 Cr.	53.3	100/41.1	44.0	52.5	0.00 %	6.38 %	2.96 %	10.0
Nectar Lifescience Ltd	190 Cr.	9.76	28.3/9.20		32.0	0.00 %	5.36 %	11.2 %	1.00
Coral Laboratories Ltd	137 Cr.	383	785/360	9.57	596	0.39 %	17.4 %	13.1 %	10.0
Industry Average	19,815.15 Cr	1,053.84		53.84	201.20	0.39%	16.35%	15.16%	6.10

All Competitor Stocks of Auro Laboratories Ltd

Quarterly Result

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	15.62	13.52	10.18	13.41	17.98	12.06	5.72	3.10	3.05	7.40	2.77	8.84	9.39
Expenses	15.17	11.17	9.02	10.38	13.90	9.65	4.39	2.38	2.60	6.59	2.74	6.49	5.33
Operating Profit	0.45	2.35	1.16	3.03	4.08	2.41	1.33	0.72	0.45	0.81	0.03	2.35	4.06
OPM %	2.88%	17.38%	11.39%	22.60%	22.69%	19.98%	23.25%	23.23%	14.75%	10.95%	1.08%	26.58%	43.24%
Other Income	0.43	0.62	0.36	0.32	0.42	0.40	0.20	0.31	0.14	0.13	0.42	0.98	0.18
Interest	0.10	0.13	0.27	0.35	0.44	-0.32	0.25	0.28	0.25	0.30	0.28	0.96	1.52
Depreciation	0.27	0.30	0.27	0.27	0.27	0.28	0.27	0.27	0.27	0.29	0.27	0.65	0.98
Profit before tax	0.51	2.54	0.98	2.73	3.79	2.85	1.01	0.48	0.07	0.35	-0.10	1.72	1.74
Tax %	27.45%	29.53%	27.55%	27.84%	27.70%	18.60%	24.75%	25.00%	28.57%	-11.43%	0.00%	58.14%	-12.07%
Net Profit	0.37	1.78	0.71	1.97	2.73	2.32	0.75	0.36	0.05	0.39	-0.11	0.72	1.95
EPS in Rs	0.59	2.86	1.14	3.16	4.38	3.72	1.20	0.58	0.08	0.63	-0.18	1.16	3.13

Last Updated: March 3, 2026, 12:04 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 11:30 pm

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	33.74	32.65	27.91	35.47	40.79	46.82	43.79	54.25	50.87	52.89	53.64	19.40	28.40
Expenses	30.95	29.71	25.11	31.03	34.43	39.83	37.51	43.01	46.24	48.50	42.96	16.00	21.15
Operating Profit	2.79	2.94	2.80	4.44	6.36	6.99	6.28	11.24	4.63	4.39	10.68	3.40	7.25
OPM %	8.27%	9.00%	10.03%	12.52%	15.59%	14.93%	14.34%	20.72%	9.10%	8.30%	19.91%	17.53%	25.53%
Other Income	0.06	0.24	0.42	0.53	0.51	0.96	0.97	0.76	1.09	0.94	1.50	0.66	1.71
Interest	1.53	1.66	1.66	1.18	1.21	0.87	0.58	0.46	0.83	0.81	0.74	1.08	3.06
Depreciation	0.74	0.72	0.68	0.86	0.93	1.01	1.02	1.04	1.02	1.07	1.09	1.10	2.19
Profit before tax	0.58	0.80	0.88	2.93	4.73	6.07	5.65	10.50	3.87	3.45	10.35	1.88	3.71
Tax %	0.00%	0.00%	0.00%	72.01%	25.16%	27.51%	27.96%	31.62%	26.61%	28.99%	24.64%	2.13%
Net Profit	0.58	0.80	0.88	0.82	3.53	4.40	4.05	7.18	2.84	2.44	7.79	1.84	2.95
EPS in Rs	0.93	1.28	1.41	1.32	5.66	7.06	6.50	11.52	4.56	3.91	12.50	2.95	4.74
Dividend Payout %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	37.93%	10.00%	-6.82%	330.49%	24.65%	-7.95%	77.28%	-60.45%	-14.08%	219.26%	-76.38%
Change in YoY Net Profit Growth (%)	0.00%	-27.93%	-16.82%	337.31%	-305.84%	-32.60%	85.24%	-137.73%	46.36%	233.35%	-295.64%

Auro Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	-5%
5 Years:	-15%
3 Years:	-27%
TTM:	-67%

Compounded Profit Growth
10 Years:	9%
5 Years:	-15%
3 Years:	-13%
TTM:	-91%

Stock Price CAGR
10 Years:	34%
5 Years:	33%
3 Years:	42%
1 Year:	23%

Return on Equity
10 Years:	15%
5 Years:	13%
3 Years:	11%
Last Year:	4%

Last Updated: September 5, 2025, 2:31 pm

Balance Sheet

Last Updated: December 10, 2025, 3:52 am

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	6.23	6.23	6.23	6.23	6.23	6.23	6.23	6.23	6.23	6.23	6.23	6.23	6.23
Reserves	0.67	1.47	2.35	3.18	6.75	11.18	15.27	22.35	25.29	27.97	35.73	36.74	37.35
Borrowings	14.80	16.41	12.62	4.95	9.20	8.09	3.16	3.16	13.78	6.41	26.25	42.72	43.94
Other Liabilities	5.14	4.67	4.49	12.45	8.23	7.97	7.68	10.15	9.66	15.38	17.52	13.40	23.25
Total Liabilities	26.84	28.78	25.69	26.81	30.41	33.47	32.34	41.89	54.96	55.99	85.73	99.09	110.77
Fixed Assets	10.51	9.80	9.13	13.00	13.02	14.59	14.24	13.56	13.61	12.62	22.15	21.06	76.84
CWIP	0.06	0.82	3.33	0.23	1.07	0.12	0.12	0.13	3.68	7.67	32.68	56.48	10.37
Investments	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05
Other Assets	16.22	18.11	13.18	13.53	16.27	18.71	17.93	28.15	37.62	35.65	30.85	21.50	23.51
Total Assets	26.84	28.78	25.69	26.81	30.41	33.47	32.34	41.89	54.96	55.99	85.73	99.09	110.77

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	4.48	-0.78	7.88	6.49	6.05	6.87	9.30	12.82	-6.59	3.28	18.81	5.75
Cash from Investing Activity +	-0.56	-0.73	-2.44	-2.20	-3.04	-3.19	-2.21	-3.51	-5.34	-5.08	-38.67	-24.45
Cash from Financing Activity +	-2.99	0.53	-5.34	-3.81	-1.77	-1.83	-5.52	-0.46	9.79	-8.18	19.09	17.69
Net Cash Flow	0.93	-0.98	0.09	0.47	1.24	1.86	1.58	8.85	-2.14	-9.98	-0.77	-1.02
Free Cash Flow	3.86	-1.55	5.36	4.86	4.25	5.25	8.63	12.44	-11.20	-0.79	18.81	5.75
CFO/OP	161%	-27%	281%	146%	95%	98%	148%	114%	-142%	75%	176%	169%

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	-12.01	-13.47	-9.82	-0.51	-2.84	-1.10	3.12	8.08	-9.15	-2.02	-15.57	-39.32

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	46.95	94.80	66.04	79.13	74.90	66.26	48.18	49.12	97.65	85.57	91.11	176.67
Inventory Days	115.33	89.37	86.72	21.65	22.00	42.98	60.54	32.60	47.32	120.27	113.24	145.45
Days Payable	62.97	56.12	72.03	80.26	78.26	66.19	70.67	73.51	54.12	117.41	85.34	246.11
Cash Conversion Cycle	99.30	128.05	80.73	20.52	18.64	43.05	38.04	8.20	90.86	88.44	119.01	76.01
Working Capital Days	19.15	39.13	26.68	67.20	64.70	63.46	51.09	29.40	36.59	104.28	35.86	-14.30
ROCE %	9.43%	10.74%	11.21%	23.06%	32.51%	29.11%	24.84%	38.87%	12.20%	9.92%	20.38%	3.85%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	52.09%	52.09%	52.09%	52.09%	52.15%	52.15%	52.15%	52.15%	52.17%	52.17%	52.17%	52.17%
DIIs	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
Public	47.90%	47.90%	47.92%	47.90%	47.85%	47.84%	47.84%	47.84%	47.82%	47.82%	47.82%	47.80%
No. of Shareholders	10,906	10,501	10,272	9,905	9,441	9,335	9,266	9,265	9,102	8,916	8,860	8,640

Shareholding Pattern Chart

No. of Shareholders

Auro Laboratories Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	2.95	12.50	3.92	4.56	11.52
Diluted EPS (Rs.)	2.95	12.50	3.92	4.56	11.52
Cash EPS (Rs.)	4.71	14.26	5.64	6.20	13.18
Book Value[Excl.RevalReserv]/Share (Rs.)	68.94	67.32	54.87	50.58	45.86
Book Value[Incl.RevalReserv]/Share (Rs.)	68.94	67.32	54.87	50.58	45.86
Revenue From Operations / Share (Rs.)	31.12	86.06	84.87	81.61	87.05
PBDIT / Share (Rs.)	6.51	19.53	8.56	9.17	19.25
PBIT / Share (Rs.)	4.75	17.78	6.83	7.54	17.59
PBT / Share (Rs.)	3.02	16.60	5.53	6.21	16.86
Net Profit / Share (Rs.)	2.95	12.50	3.92	4.56	11.52
PBDIT Margin (%)	20.92	22.69	10.08	11.24	22.11
PBIT Margin (%)	15.27	20.66	8.05	9.24	20.20
PBT Margin (%)	9.69	19.28	6.51	7.61	19.36
Net Profit Margin (%)	9.47	14.52	4.61	5.59	13.23
Return on Networth / Equity (%)	4.27	18.57	7.14	9.02	25.11
Return on Capital Employeed (%)	3.82	17.93	11.25	13.49	32.80
Return On Assets (%)	1.85	9.08	4.36	5.17	17.13
Long Term Debt / Equity (X)	0.71	0.43	0.05	0.02	0.07
Total Debt / Equity (X)	0.99	0.62	0.18	0.02	0.07
Asset Turnover Ratio (%)	0.20	0.75	0.95	1.05	1.46
Current Ratio (X)	0.99	1.29	1.97	1.87	3.32
Quick Ratio (X)	0.82	0.94	1.32	1.66	3.02
Inventory Turnover Ratio (X)	3.26	2.90	4.66	9.92	8.30
Interest Coverage Ratio (X)	3.75	16.55	6.55	6.92	26.18
Interest Coverage Ratio (Post Tax) (X)	2.70	11.59	4.00	4.44	16.66
Enterprise Value (Cr.)	185.78	125.03	37.80	50.97	38.05
EV / Net Operating Revenue (X)	9.58	2.33	0.71	1.00	0.70
EV / EBITDA (X)	45.76	10.27	7.09	8.91	3.17
MarketCap / Net Operating Revenue (X)	7.41	1.87	0.64	1.23	0.93
Price / BV (X)	3.34	2.39	0.99	1.98	1.77
Price / Net Operating Revenue (X)	7.41	1.87	0.64	1.23	0.93
EarningsYield	0.01	0.07	0.07	0.04	0.14

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Auro Laboratories Ltd. is a Public Limited Listed company incorporated on 26/05/1989 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L33125MH1989PLC051910 and registration number is 051910. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 19.40 Cr. and Equity Capital is Rs. 6.23 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	K-56, M.I.D.C. Industrial Area, Palghar District Maharashtra 401506	Contact not found

Management
Name	Position Held
Mr. Sharat Deorah	Chairman & Managing Director
Mr. Kiran Suresh Kulkarni	Whole Time Director
Mr. Siddhartha Deorah	Whole Time Director
Mr. Mahendra Kumar Daga	Ind. Non-Executive Director
Mrs. Kavita Vijayakant Sharma	Ind. Non-Executive Director
Mr. Vishal Kailashchandra Jhunjhunwala	Ind. Non-Executive Director

FAQ

What is the intrinsic value of Auro Laboratories Ltd and is it undervalued?

As of 25 April 2026, Auro Laboratories Ltd's intrinsic value is ₹134.72, which is 50.47% lower than the current market price of ₹272.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (4.33 %), book value (₹69.9), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Auro Laboratories Ltd?

Auro Laboratories Ltd is trading at ₹272.00 as of 25 April 2026, with a FY2026-2027 high of ₹317 and low of ₹159. The stock is currently in the middle of its 52-week range. Market cap stands at ₹169 Cr..

How does Auro Laboratories Ltd's P/E ratio compare to its industry?

Auro Laboratories Ltd has a P/E ratio of 57.4, which is above the industry average of 53.84. The premium over industry average may reflect growth expectations or speculative interest.

Is Auro Laboratories Ltd financially healthy?

Key indicators for Auro Laboratories Ltd: ROCE of 3.85 % is on the lower side compared to the industry average of 16.35%; ROE of 4.33 % is below ideal levels (industry average: 15.16%). Dividend yield is 0.00 %.

Is Auro Laboratories Ltd profitable and how is the profit trend?

Auro Laboratories Ltd reported a net profit of ₹2 Cr in Mar 2025 on revenue of ₹19 Cr. Compared to ₹3 Cr in Mar 2022, the net profit shows a declining trend.

Does Auro Laboratories Ltd pay dividends?

Auro Laboratories Ltd has a dividend yield of 0.00 % at the current price of ₹272.00. The company is currently not paying meaningful dividends.